Introduction
Multiple myeloma (MM) is a relatively rare malignant plasma cell disorder. It constitutes, however, the second most common haematologic malignancy. In the course of the disease, excessive loads of monoclonal immunoglobulins or their free light chain components result in clinical symptoms such as hypercalcaemia, renal insuffi ciency, anaemia or osteolytic bone lesions (CRAB) [1] and, rarely, light chain amyloidosis (AL). Accordingly, pain, fatigue and bone pain constitute the most common signs of the disease beside a variety of unspecifi c symptoms like early osteoporosis.
Today, MM is still considered incurable despite the introduction of novel therapies, such as thalidomide, bortezomib and lenalidomide in the last decade. In patients <65 years of age, induction therapy comprising one of these new drugs followed by high-dose melphalan and autologous stem cell transplantation is currently the treatment of choice [2] .
Here, we report the case of a patient with poor prognosis based on genetic risk factors (del17p), who was refractory to a bortezomib containing regimen and did not tolerate subsequent combination therapy with thalidomide/dexamethasone (Th al/Dex), but experienced long-lasting disease control with continuous low-dose lenalidomide monotherapy.
Case report
In October 2005, a 60-year-old female patient was admitted to the Medical University Hospital in Innsbruck. She had preexisting osteoporosis and had suff ered from back pain for twelve months. During work-up by a rheumatologist, pathological serum electrophoresis results were discovered and the patient was transferred to our haematology department. Apart from pain in the spinal column and right rib area, the physical examination was uneventful. Initial laboratory tests revealed monoclonal gammopathy with IgG kappa (IgG-k) light chains and mild anaemia (Table 1) . A full skeletal x-ray survey showed no bone destruction, but an MRI scan revealed osteolysis at the third right rib as well as bone-marrow infi ltration. In addition, we observed multiple spotted areas ("salt and pepper") in the spine compatible with a diff use infi ltration of the vertebrae. Bone marrow histology showed increased clonal plasma cells at 50%, with distinct areas of up to 90%. Fluorescent in-situ hybridisation (FISH) revealed partial deletions of chromosomes 13 (del13q) and 17 (del17p) indicating poor prognosis [3] . Based on these fi ndings, the patient was diagnosed with high-risk IgG kappa MM stage IA according to Durie & Salmon [4] and stage I according to the International Staging System (ISS) [5] , respectively. She refused any treatment and therefore, underwent periodic monitoring.
In Additionally, multiple osteolyses were present that required vertebroplasty on the collapsed lumbar vertebra III. Ibandronic acid was given intravenously every four weeks. After the second cycle, VD treatment was terminated due to progressive disease (M-protein, 5.09 g/dL; plasma cells in a bone-marrow biopsy, 70%; haemoglobin, 7.6 g/dL). By the end of September 2006, we initiated therapy with thalidomide 100 mg orally per day and dexamethasone 40 mg orally on days 1-4, 9-12, 17-20. At the same time the patient underwent a radiation therapy on the thoracic spine and the os ilium (10-11/2006 ) in order to alleviate pain. Th e Th al/Dex treatment was given over 11 months and resulted in a partial response (PR) (M-protein, 0.61 g/dl; FLC-k, 285 mg/L) (Fig. 1) . In July 2007, the patient again underwent radiotherapy for pain relief at the thoracic spine.
However, in September 2007 the treatment had to be discontinued because of painful peripheral neuropathy WHO grade III despite reduction of the thalidomide dose. At this point, the patient once again refused autologous stem cell transplantation (ASCT) and also any further cytoreductive therapy. Due to disease progression and after intensive discussion with the patient, we initiated lenalidomide orally at 10 mg daily in 11/2007. In view of the pre-existing osteoporosis and the intention of long-term administration, no steroid was added. At this time, M-protein in serum was 1.49 g/dL and FLC-k was 632 mg/L. Renal function was normal. Th e new regimen led to a very good partial response (VGPR) [6] In the course of the long-term lenalidomide treatment, thalidomide-induced neuropathy improved gradually from WHO grade III to grade I. Th e patient developed low-grade leukopenia (CTC grade I) but had no other adverse events.
Almost four years after the onset of treatment with lenalidomide, the patient is still in partial remission and apart from pre-existing pain due to degenerative bone disease requiring analgesics in a good clinical state.
Discussion
Recent years have seen substantial progress towards understanding the pathogenesis of MM, including the discovery of genetic alterations in the myeloma cells with prognostic signifi cance [7] . Deletion 17p, which was also detected in our patient, is considered to be a relatively reliable indicator of a poor prognosis. Th is was demonstrated by the French Myeloma Study Group which reported event-free survival of 15 months in patients with del17p versus 35 months in patients without del17p, based on more than a thousand patients treated with conventional chemotherapy followed by transplantation. Th e overall survival for patients with del17p was limited to 22 months versus 75% of patients without del17p still being alive at 41 months (time of median follow-up, median not reached) [7] . Accordingly, a recently published update on risk stratifi cation of newly diagnosed MM considers the presence of del17p a high-risk diagnostic fi nding [3] .
For several years now, new potent drugs, such as thalidomide, bortezomib and lenalidomide, with a mode of action distinct from that of classical cytoreductive agents, have been available [8, 9] . While the application of "old" induction regimes consisting of vincristine, doxorubicine, dexamethasone (VAD) led to a complete remission (CR) in only about 5% of patients, combination regimens including the abovementioned new drugs produced CR-rates of around 30% [2] . Th e high remission rates obtained with these novel substances translate into an improved survival not only in younger but also in elderly patients not eligible for transplantation. When tolerated, however, these impressive results can be further improved by high-dose melphalan followed by ASCT.
Th e 60-year-old female patient described here had been diagnosed with high-risk myeloma defi ned by the presence of a double del17p and del13q in the malignant cells. Due to these high-risk features and the presence of renal impairment, she received a bortezomib-based induction regimen. Unfortunately the disease progressed during treatment and therefore, she was switched to Th al/Dex. Th erapy was successful but led to a peripheral neuropathy that rendered further use of the drug impossible. In the light of the patient's anxious personality, persistence issues and the preexisting severe neuropathy, we decided on an attenuated maintenance therapy comprising lenalidomide 10 mg, daily. Th is is a considerably lower dose than that recommended in the Summary of Product Characteristics (25 mg daily on days 1-21 of repeated 28-day cycles) [10] . In a recent study by the German Refractory Myeloma Study Group, however, a reduced lenalidomide dose (median 15 mg/d on day 1-21 of 28) combined with dexamethasone (28 mg on days 1-4, 9-12 und 17-20) demonstrated promising effi cacy and safety in ten patients with relapsed and refractory MM [11] . With this regimen, the median duration of treatment was 15 months and the median event-free survival 4 months. Although our dose was even lower (10 mg, daily), our patient experienced a considerably longer event-free period even without dexamethasone. Tolerability of lenalidomide was excellent over the entire treatment period. Apart from low-grade leucopenia no further toxicities were observed -not even anemia or thrombocytopenia, two of the most often reported side eff ects of lenalidomide [10] . In our patient, peripheral neuropathy, a recognised neurotoxic eff ect of thalidomide [12] , was a limiting factor for this therapy. Although it is an analogue of thalidomide, the effi cacy and safety profi le of lenalidomide is diff erent and includes hardly any reports of neuropathies [10] .
Our patient has experienced a substantial level of disease control using continuous low-dose treatment, which has now lasted for 4 years. Th e good tolerability over several years makes lenalidomide a feasible option especially for sensitive or heavily pre-treated patients unable to tolerate other more stressful regimens. Beyond that, patients with relapsed and refractory MM ineligible for ASCT may benefi t from low-dose lenalidomide monotherapy. Based on these observations, we think that there is a rationale for prolonged lenalidomide treatment in high-risk patients with relapsed or refractory MM who cannot or do not want to undergo ASCT. A tailored dose of lenalidomide is well tolerated and can be given over prolonged periods.
